Navigation Links
Crucell Announces New Award of $110 Million for Paediatric Vaccine Quinvaxem(R) by UNICEF to Support Vaccination Programs in the Developing World
Date:5/6/2010

is, Haemoplilus influenza type b infection and hepatitis B. Quinvaxem(R) is ready for use without further preparation steps by healthcare workers in the field, which offers major healthcare advantages for these countries with a challenging infrastructure and hygiene problems.

This latest order brings the overall value of tenders awarded to Crucell for the period of 2010-2012 to $410 million. This is in addition to the $500 million obtained over the tender period 2007-2009. They bring the total value of contracts awarded since the launch of Quinvaxem(R) at the end of 2006 to $910 million. During the first tender round in 2006, Crucell was initially awarded $230 million (December 2006) and received additional incremental awards of $130 million and $140 million in May and September 2008, respectively.

Forward-looking statements

This press release contains forward-looking statements that involve inherent risks and uncertainties. We have identified certain important factors that may cause actual results to differ materially from those contained in such forward-looking statements. For information relating to these factors please refer to our Form 20-F, as filed with the US Securities and Exchange Commission on April 7, 2010, in the section entitled 'Risk Factors'. The Company prepares its financial statements under International Financial Reporting Standards (IFRS).

About Crucell

Crucell N.V. (NYSE Euronext, NASDAQ: CRXL<
'/>"/>

SOURCE Crucell N.V
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. DSM and Crucell Announce Another Key Achievement for PER.C6(R) Technology; Scale Up of High-Titer Fed-Batch Process to 250 Liters
2. DSM Biologics and Crucell Announce Commercial PER.C6(R) Licensing Agreement with Gedeon Richter
3. DSM and Crucell Sign Agreement with Bioceros to Serve as Pre-Approved Cell Line Generation Partner of PER.C6(R) Cell Line Proteins
4. Confirmation of Bogoch Replikins Influenza Patents by Harvard-CDC and Scripps-Crucell Data
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
7. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
8. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
9. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
10. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... March 30, 2015 With recent advancements ... you the government, major companies are getting into the ... setting future mandates for renewable energy production, many homeowners ... , Solara Power is a new solar distribution company ... available that allow qualifying homeowners to enjoy the benefits ...
(Date:3/30/2015)... March 30, 2015  NuGene International, Inc. ("NuGene") ... NuGene BioPharma, Inc. has added another internationally recognized ... Guan is an internationally recognized researcher in bio-inspired ... education at Peking University, China ... the University of North Carolina, Chapel Hill. Following ...
(Date:3/30/2015)... OTTAWA , March 30, 2015 /CNW/ - A ... today on the salaries and demographic profiles of new ... "Opening the Door – Building Careers for New Grads ... Canada,s Research-Based Pharmaceutical Companies (Rx&D) and features ... federal Career Focus wage subsidy program from 2013 to ...
(Date:3/30/2015)... England , March 30, 2015 ... developing novel biological drugs to treat cancer, viral ... of Professor Sir John Bell , the ... Chairman of the Office for the Strategic Coordination ... with immediate effect.      (Photo: ...
Breaking Biology Technology:Solara Power Announces Residential Solar Power with No Up-Front Fees 2UCI Professor Zhibin Guan Joins NuGene Advisory Board 2UCI Professor Zhibin Guan Joins NuGene Advisory Board 3New Report on Graduates in Canadian Biotech Industry Sheds Light on Hiring Practices 2New Report on Graduates in Canadian Biotech Industry Sheds Light on Hiring Practices 3New Report on Graduates in Canadian Biotech Industry Sheds Light on Hiring Practices 4Immunocore Appoints Professor Sir John Bell to its Board of Directors 2Immunocore Appoints Professor Sir John Bell to its Board of Directors 3Immunocore Appoints Professor Sir John Bell to its Board of Directors 4Immunocore Appoints Professor Sir John Bell to its Board of Directors 5
... Towards Creating Patient-Specific and Disease-Specific ... Stem Cells For Therapeutic Use, LA JOLLA, ... company, announced today it has become the,first in the world to ... transfer (SCNT)., Stemagen CEO Samuel H. Wood, M.D., Ph.D., a ...
... Former Electrophysiologist at Cleveland Clinic Brings Extensive Experience, in the ... ... of Cardiovascular Disease, ST. LOUIS, Jan. 17 ... Burkhardt, M.D.,F.A.C.C., as Chief Medical Officer. Dr. Burkhardt was most ...
... /Xinhua-PRNewswire-FirstCall/ -- Pharmaxis (ASX: PXS;,Nasdaq: PXSL) today announced ... its asthma management product, Aridol., "This is ... Chief,Executive Officer Dr Alan Robertson. "Korea is an ... in Asia. There are an estimated 2.5 million,asthma ...
Cached Biology Technology:Stemagen First to Create Cloned Human Embryos From Adult Cells 2Stemagen First to Create Cloned Human Embryos From Adult Cells 3Stereotaxis Appoints David Burkhardt, M.D. as Chief Medical Officer 2Stereotaxis Appoints David Burkhardt, M.D. as Chief Medical Officer 3Pharmaxis' Aridol Gains First Asian Approval 2
(Date:3/10/2015)... , March 10, 2015  Continuing its 167-year ... Unexpected, Hammacher Schlemmer introduces The Eye Scanning Password ... before granting access to secure websites or sensitive data. ... verify travelers at international borders, the device has a ... pattern points of the iris, converting them into an ...
(Date:3/10/2015)... Conn. , March 10, 2015  NXT-ID, ... ("NXT-ID" or the "Company"), a biometric authentication company ... the company,s Wocket™ smart wallet has been named ... by Rethink Modern. Rethink Modern ( ... and innovative items for your home and lifestyle that have ...
(Date:3/3/2015)... , March 3, 2015 ... provider of advanced cryogenic logistics solutions for ... immunotherapies, stem cells, cell lines, clinical research ... medicine, today announced the expansion of its ... Centers, ("Fred Hutch") Clinical Research Division ...
Breaking Biology News(10 mins):Hammacher Schlemmer Introduces The Eye Scanning Password Authenticator 2NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 2NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 3NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 4Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 2Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 3
... the word "herpes" usually conjures negative images and stereotypes, but ... virus. For most, a sore appears, heals and is forgotten, ... circumstances to come back. Now, the mystery behind what triggers ... solved thanks to new research published in the ...
... Scientists have identified a molecular ,flag, in women with breast ... the hormone drug tamoxifen. Tamoxifen used alongside traditional ... in certain breast cancers, is required by the tumour to ... by up to one third. However, about one third ...
... cells grow fast. That,s an essential characteristic of what makes ... and are continuously growing and dividing, far outstripping our normal ... metabolism. CSHL Professor Adrian Krainer and his team ... process and in the process specifically kill cancer cells. ...
Cached Biology News:How and why herpes viruses reactivate to cause disease 2Scientists unravel resistance to breast cancer treatment 2Team uses antisense technology that exploits gene splicing mechanism to kill cancer cells 2Team uses antisense technology that exploits gene splicing mechanism to kill cancer cells 3
Human TGF-beta RIIb Affinity Purified Polyclonal Ab...
Human FGF R2 (alpha isoforms) MAb (Clone 98706)...
dithiothreitol, sulfhydryl reducing agent, C4H10O2S2; MW: 154.24, 97% pure (minimum), CAS No: 27565-41-9, store at -20 C ...
... Nucleon HT, 1 kit. Facilitates the ... paraffin-embedded sections and hard tissue requiring proteinase ... high quality DNA from 50 preparations of ... Category: DNA/RNA Synthesis & Purification, Purification and ...
Biology Products: